355 ALHAMBRA CIRCLE, CORAL GABLES, FL
Merger Agreement Completed - Catalyst Pharmaceuticals and Angelini Pharma
Material disclosure
Demonstrates On-Target Glucocorticoid Activity Without the Immunosuppression Characteristic of Traditional Corticosteroids at Clinical Doses
Other Events
Reports First Quarter 2026 Financial Results
Announces Settlement of FIRDAPSE® (amifampridine) Patent Litigation with Hetero Labs Ltd.
Amended material disclosure
Q1
Amended Annual Report
FY 2024
Q3
Q2
FY 2023
Notice of Suspension of Duty to File Reports
Effectiveness Notice
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(5)
Additional Proxy Materials
Definitive Merger Proxy Statement
Definitive Proxy Statement
Statement of Changes in Beneficial Ownership
S-8 POS
Post-Effective Amendment to Registration Statement
Automatic Shelf Registration Statement